DE60129934T2 - Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie - Google Patents

Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie Download PDF

Info

Publication number
DE60129934T2
DE60129934T2 DE60129934T DE60129934T DE60129934T2 DE 60129934 T2 DE60129934 T2 DE 60129934T2 DE 60129934 T DE60129934 T DE 60129934T DE 60129934 T DE60129934 T DE 60129934T DE 60129934 T2 DE60129934 T2 DE 60129934T2
Authority
DE
Germany
Prior art keywords
sub
formula
hydrogen
tyrosine kinase
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60129934T
Other languages
German (de)
English (en)
Other versions
DE60129934D1 (de
Inventor
Robert Charles Canterbury ATKINS
Steven James Blackrock Chadban
Mark Emmanuel Kew COOPER
Richard Ernest West St. Kilda Gilbert
Prudence Ann Canterbury Hill
Darren James Chirnside Village Kelly
David John Pearcedale Nikolic-Paterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NIKOLIC PATERSON DAVID JOHN
University of Melbourne
Southern Health
Novartis AG
Original Assignee
NIKOLIC PATERSON DAVID JOHN
University of Melbourne
Southern Health
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NIKOLIC PATERSON DAVID JOHN, University of Melbourne, Southern Health, Novartis AG filed Critical NIKOLIC PATERSON DAVID JOHN
Publication of DE60129934D1 publication Critical patent/DE60129934D1/de
Application granted granted Critical
Publication of DE60129934T2 publication Critical patent/DE60129934T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60129934T 2000-03-03 2001-03-01 Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie Expired - Lifetime DE60129934T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00810181 2000-03-03
EP00810181 2000-03-03
PCT/EP2001/002340 WO2001064200A2 (en) 2000-03-03 2001-03-01 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy

Publications (2)

Publication Number Publication Date
DE60129934D1 DE60129934D1 (de) 2007-09-27
DE60129934T2 true DE60129934T2 (de) 2008-05-08

Family

ID=8174580

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60129934T Expired - Lifetime DE60129934T2 (de) 2000-03-03 2001-03-01 Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie

Country Status (10)

Country Link
US (1) US7087608B2 (enExample)
EP (1) EP1259242B1 (enExample)
JP (1) JP2003525240A (enExample)
AT (1) ATE369860T1 (enExample)
AU (2) AU2001248324B2 (enExample)
CA (1) CA2401812C (enExample)
DE (1) DE60129934T2 (enExample)
ES (1) ES2291306T3 (enExample)
PT (1) PT1259242E (enExample)
WO (1) WO2001064200A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1408978A4 (en) 2001-06-21 2005-07-13 Ariad Pharma Inc NOVEL PHENYLAMINO-PYRIMIDINES AND THEIR USE
US7741335B2 (en) 2001-06-29 2010-06-22 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
JP2004537536A (ja) 2001-06-29 2004-12-16 アブ サイエンス アレルギー疾患を治療するためのチロシンキナーゼ阻害剤の使用方法
JP2005500041A (ja) 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
US7678805B2 (en) 2001-06-29 2010-03-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
PL369123A1 (en) * 2001-08-25 2005-04-18 Arakis Ltd. The use of anthroquinones in the treatment of kidney disease
US7332330B2 (en) * 2001-09-11 2008-02-19 Renamed Biologics, Inc. Device for maintaining vascularization near an implant
IL162838A0 (en) 2002-01-04 2005-11-20 Univ Rockefeller Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
AU2003232115A1 (en) * 2002-05-13 2003-11-11 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of graft failure
PT1525200E (pt) 2002-08-02 2008-01-10 Ab Science 2-(3-aminoaril)amino-4-aril-tiazóis para o tratamento de doenças
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
NZ543709A (en) * 2003-05-27 2009-04-30 Robert Per Hagerkvist Use of tyrosine kinase inhibitor to treat diabetes
WO2005016323A2 (en) * 2003-08-15 2005-02-24 Ab Science Use of c-kit inhibitors for treating type ii diabetes
CN1905876B (zh) 2003-11-17 2010-06-09 诺瓦提斯公司 二肽基肽酶iv抑制剂的用途
EP2125895B1 (en) 2007-02-02 2015-04-08 Vegenics Pty Ltd Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
WO2009143389A1 (en) 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
JP6166534B2 (ja) 2009-08-05 2017-07-19 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規調節タンパク質および阻害剤
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN107573322A (zh) * 2017-09-06 2018-01-12 南京优科生物医药研究有限公司 伊马替尼双氮氧化物、其制备方法和用途
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
JP2602735B2 (ja) * 1989-09-27 1997-04-23 株式会社大塚製薬工場 抗活性酸素剤
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
JP3810020B2 (ja) 1993-04-22 2006-08-16 武田薬品工業株式会社 腎疾患の予防または治療剤
US5795910A (en) 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US5721277A (en) 1995-04-21 1998-02-24 Sugen, Inc. Compounds and methods for inhibiting hyper-proliferative cell growth
CA2214393A1 (en) 1996-09-02 1998-03-02 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JPH10182644A (ja) * 1996-11-01 1998-07-07 Takeda Chem Ind Ltd 三環性化合物、その製造法及び剤
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9809869D0 (en) 1998-05-09 1998-07-08 Medical Res Council Inhibition of protein kinases
AR028802A1 (es) 1998-08-13 2003-05-28 Novartis Ag El uso de ciertos compuestos de ftalazina para el tratamiento de enfermedades neovasculares oculares

Also Published As

Publication number Publication date
AU4832401A (en) 2001-09-12
HK1052864A1 (en) 2003-10-03
WO2001064200A3 (en) 2002-01-17
DE60129934D1 (de) 2007-09-27
US20030186977A1 (en) 2003-10-02
CA2401812A1 (en) 2001-09-07
EP1259242A2 (en) 2002-11-27
JP2003525240A (ja) 2003-08-26
WO2001064200A2 (en) 2001-09-07
CA2401812C (en) 2009-06-09
AU2001248324B2 (en) 2005-09-15
US7087608B2 (en) 2006-08-08
ES2291306T3 (es) 2008-03-01
ATE369860T1 (de) 2007-09-15
EP1259242B1 (en) 2007-08-15
PT1259242E (pt) 2007-11-15

Similar Documents

Publication Publication Date Title
DE60129934T2 (de) Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie
DE60014361T2 (de) Zyklische aminderivate und ihre verwendung
DE69937997T2 (de) Inhibitoren des transkriptionsfaktors nf-kappa b
DE69017302T2 (de) Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
DE69309094T2 (de) Hemmung der TNF - Bildung
DE60212836T2 (de) Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
DE69631134T2 (de) Verfahren zur bekämpfung infektiöser krankheiten unter verwendung dikationischer bis-benzimidazole
EP1176963B1 (de) Verwendung von dopamin-d 3-rezeptorantagonisten zur herstellung von arzneimittel für die behandlung von nierenfunktionsstörungen
DE69900207T2 (de) Verwendung von 11-(3-dimethylaminopropyliden)-6,11-dihydrodibenz[b,e]oxepin-2-essigsäure und deren pharmazeutisch annehmbaren salzen zur herstellung eines medikaments zur behandlung nicht-allergisch-bedingten augenentzündungen und zur prevention der okularen neovaskularisation
DE60030338T2 (de) Verwendung von 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin und deren physiologisch akzeptablen Salzen
AU2001248324A1 (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
DE60129518T2 (de) Verwendung von einem Vasopressin-Antagonisten wie Conivaptan zur Herstellung eines Medikaments für die Behandlung der pulmonalen Hypertension
DE60308337T2 (de) 4-(4-Methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyrimidin-3-yl)pyrimidin-2-ylamino)phenylbenzamid zur Behandlung von Ang II vermitteltern Erkrankungen
SK12312003A3 (sk) Použitie N-fenyl-2-pyridínamínových derivátov proti ochoreniam s účasťou žírnych buniek
DE69302646T2 (de) Benzimidazolverbindungen als Antibiotika gegen Campylobacter pylon
DE69933450T2 (de) Imidazolin-rezeptor-bindende verbindungen
DE60306896T2 (de) Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen
DE69917005T2 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
DE60130030T2 (de) Verfahren zur behandlung von glaukom
DE69003924T2 (de) Verhinderung von Entzugserscheinungen.
DE60307265T2 (de) Verwendung des metabolits von valsartan zur hemmung der thrombozytenaggregation
DE69029814T2 (de) Inhibitoren der dihydrofolatreduktase von pneumocystis carinii
DE60210783T2 (de) Nicht-peptidische ccr1-rezeptor-antagonisten zur behandlung der progressiven nierenfibrose
DE69501944T2 (de) Arzneimittel zur Vorbeugung oder Behandlung von chronischem Rheumatismus und Sepsis
EP1517687B1 (de) Arzneimittel zur behandlung des "systemic inflammatory response syndrome"

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 80336 MUENCHEN